New cancer drug safety test halted after early phase
Disease control
Terminated
This early-stage study tested the safety of a new cancer drug called ZL-1218, both alone and combined with an existing immunotherapy. It involved 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find safe dosage levels …
Phase: PHASE1 • Sponsor: Zai Lab (Hong Kong), Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC